Cardio-oncology is an emerging field focusing on the detection, monitoring, and treatment of cardiac dysfunction related to systemic or radiation therapy.
The addition of trastuzumab to adjuvant chemotherapy did not improve outcomes for patients with HER2-low invasive breast cancer, a phase 3 randomized trial showed.
In a randomized phase 3 trial, researchers sought to determine if cetuximab-based chemoradiotherapy could be a less-toxic alternative to cisplatin-based chemoradiotherapy in patients with HPV-positive oropharyngeal cancer.
Cinvanti injectable emulsion can be administered as a 2-minute intravenous injection or 30-minute intravenous infusion.
Measuring a tumor’s response to neoadjuvant chemotherapy can be prognostic, providing important clues about a patient’s likely outcome following treatment.
An evaluation of patient education materials on chemotherapy for breast cancer revealed that many do not meet NIH recommendations.
Maintaining full doses of chemo especially important early in the treatment course.
Results of a phase 1/2 trial demonstrated the efficacy of nelfinavir in combination with lenalidomide and dexamethasone for lenalidomide-refractory MM.
There are few observational studies examining patients with aNSCLC who have been treated with immune checkpoint inhibitor therapy.
There are few clinical trials examining immune checkpoint inhibitor therapy in advanced NSCLC that enroll a high percentage of Asian patients.
